1-Alkyl-2-acetylglycerophosphocholine Esterase
A lipoprotein-associated PHOSPHOLIPASE A2 which modulates the action of PLATELET ACTIVATING FACTOR by hydrolyzing the SN-2 ester bond to yield the biologically inactive lyso-platelet-activating factor. It has specificity for phospholipid substrates with short-chain residues at the SN-2 position, but inactive against long-chain phospholipids. Deficiency in this enzyme is associated with many diseases including ASTHMA, and HYPERCHOLESTEROLEMIA.
Carboxylic Ester Hydrolases
Naphthol AS D Esterase
Sterol Esterase
Acetylesterase
Carboxylesterase
Isoflurophate
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. (1/562)
A novel and potent azetidinone inhibitor of the lipoprotein-associated phospholipase A2 (Lp-PLA2), i.e. platelet-activating factor acetylhydrolase, is described for the first time. This inhibitor, SB-222657 (Ki=40+/-3 nM, kobs/[I]=6. 6x10(5) M-1.s-1), is inactive against paraoxonase, is a poor inhibitor of lecithin:cholesterol acyltransferase and has been used to investigate the role of Lp-PLA2 in the oxidative modification of lipoproteins. Although pretreatment with SB-222657 did not affect the kinetics of low-density lipoprotein (LDL) oxidation by Cu2+ or an azo free-radical generator as determined by assay of lipid hydroperoxides (LOOHs), conjugated dienes and thiobarbituric acid-reacting substances, in both cases it inhibited the elevation in lysophosphatidylcholine content. Moreover, the significantly increased monocyte chemoattractant activity found in a non-esterified fatty acid fraction from LDL oxidized by Cu2+ was also prevented by pretreatment with SB-222657, with an IC50 value of 5.0+/-0.4 nM. The less potent diastereoisomer of SB-222657, SB-223777 (Ki=6.3+/-0.5 microM, kobs/[I]=1.6x10(4) M-1.s-1), was found to be significantly less active in both assays. Thus, in addition to generating lysophosphatidylcholine, a known biologically active lipid, these results demonstrate that Lp-PLA2 is capable of generating oxidized non-esterified fatty acid moieties that are also bioactive. These findings are consistent with our proposal that Lp-PLA2 has a predominantly pro-inflammatory role in atherogenesis. Finally, similar studies have demonstrated that a different situation exists during the oxidation of high-density lipoprotein, with enzyme(s) other than Lp-PLA2 apparently being responsible for generating lysophosphatidylcholine. (+info)Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. (2/562)
OBJECTIVE: To investigate the relationship between the quantitative and qualitative abnormalities of apolipoprotein B (Apo B)- and Apo A-I-containing lipoproteins and between lipoprotein-associated platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with juvenile rheumatoid arthritis (JRA) as a function of the inflammatory state. METHODS: Twenty-six JRA patients and 22 age- and sex-matched control subjects with normal lipid levels participated in the study. Fourteen patients had active disease, and 12 had inactive disease. Plasma lipoproteins were fractionated by gradient ultracentrifugation into 9 subfractions, and their chemical composition and mass were determined. The PAF-AH activity associated with lipoprotein subfractions and the activity in plasma were also measured. RESULTS: Patients with active JRA had significantly lower plasma total cholesterol and high-density lipoprotein (HDL) cholesterol levels as compared with controls, due to the decrease in the mass of both the HDL2 and HDL3 subfractions. Patients with active JRA also had higher plasma triglyceride levels, mainly due to the higher triglyceride content of the very low-density lipoprotein plus the intermediate-density lipoprotein subfraction. The plasma PAF-AH activity in patients with active JRA was lower than that in controls, mainly due to the decrease in PAF-AH activity associated with the intermediate and dense low-density lipoprotein subclasses. The lipid abnormalities and the reduction in plasma PAF-AH activity were significantly correlated with plasma C-reactive protein levels and were not observed in patients with inactive JRA. CONCLUSION: This is the first study to show that patients with active JRA exhibit low levels of HDL2 and HDL3 and are deficient in plasma PAF-AH activity. These alterations suggest that active JRA is associated with partial loss of the antiinflammatory activity of plasma Apo B- and Apo A-I-containing lipoproteins. (+info)Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death. (3/562)
Glutamate receptors modulate multiple signaling pathways, several of which involve mitogen-activated protein (MAP) kinases, with subsequent physiological or pathological consequences. Here we report that stimulation of the N-methyl-D-aspartate (NMDA) receptor, using platelet-activating factor (PAF) as a messenger, activates MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase, in primary cultures of hippocampal neurons. Activation of the metabotropic glutamate receptor (mGluR) blocks this NMDA-signaling through PAF and MAP kinases, and the resultant cell death. Recombinant PAF-acetylhydrolase degrades PAF generated by NMDA-receptor activation; the hetrazepine BN50730 (an intracellular PAF receptor antagonist) also inhibits both NMDA-stimulated MAP kinases and neuronal cell death. The finding that the NMDA receptor-PAF-MAP kinase signaling pathway is attenuated by mGluR activation highlights the exquisite interplay between glutamate receptors in the decision making process between neuronal survival and death. (+info)Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. (4/562)
The platelet-activating factor acetylhydrolases are enzymes that were initially characterized by their ability to hydrolyze platelet-activating factor (PAF). In human plasma, PAF acetylhydrolase (EC 3.1.1.47) circulates in a complex with low density lipoproteins (LDL) and high density lipoproteins (HDL). This association defines the physical state of PAF acetylhydrolase, confers a long half-life, and is a major determinant of its catalytic efficiency in vivo. The lipoprotein-associated enzyme accounts for all of the PAF hydrolysis in plasma but only two-thirds of the protein mass. To characterize the enzyme-lipoprotein interaction, we employed site-directed mutagenesis techniques. Two domains within the primary sequence of human PAF acetylhydrolase, tyrosine 205 and residues 115 and 116, were important for its binding to LDL. Mutation or deletion of those sequences prevented the association of the enzyme with lipoproteins. When residues 115 and 116 from human PAF acetylhydrolase were introduced into mouse PAF acetylhydrolase (which normally does not associate with LDL), the mutant mouse PAF acetylhydrolase associated with lipoproteins. To analyze the role of apolipoprotein (apo) B100 in the formation of the PAF acetylhydrolase-LDL complex, we tested the ability of PAF acetylhydrolase to bind to lipoproteins containing truncated forms of apoB. These studies indicated that the carboxyl terminus of apoB plays a key role in the association of PAF acetylhydrolase with LDL. These data on the molecular basis of the PAF acetylhydrolase-LDL association provide a new level of understanding regarding the pathway for the catabolism of PAF in human blood. (+info)Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. (5/562)
Asthma, a family of airway disorders characterized by airway inflammation, has an increasing incidence worldwide. Platelet-activating factor (PAF) may play a role in the pathophysiology of asthma. Its proinflammatory actions are antagonized by PAF acetylhydrolase. A missense mutation (V279F) in the PAF acetylhydrolase gene results in the complete loss of activity, which occurs in 4% of the Japanese population. We asked if PAF acetylhydrolase deficiency correlates with the incidence and severity of asthma in Japan. We found that the prevalence of PAF acetylhydrolase deficiency is higher in Japanese asthmatics than healthy subjects and that the severity of this syndrome is highest in homozygous-deficient subjects. We conclude that the PAF acetylhydrolase gene is a modulating locus for the severity of asthma. (+info)Platelet-activating factor may act as an endogenous pulse generator for sheep of luteolytic PGF2alpha release. (6/562)
Pulsatile release of uterine prostaglandin F2alpha (PGF2alpha) induces luteolysis in ruminants. However, the mechanism(s) that initiates and maintains luteolysis has not been defined. The present study tested the hypothesis that the endogenous PGF2alpha pulse generator is uterine-derived platelet-activating factor (PAF). Ovariectomized ewes were given exogenous progesterone (P), estradiol (E), or both (P+E, mimicking the normal luteal phase). Only ewes treated with steroids released PAF into the uterine lumen and had increased PAF:acetylhydrolase activity in the uterine lumen. Steroid treatment also influenced the capacity of the uterus to release PGF2alpha in response to exogenous PAF. PAF infusion did not affect plasma PGF2alpha metabolite (PGFM) levels in control (no steroid treatment) ewes but increased plasma PGFM levels in P+E ewes (P < 0.001) and ewes treated with P or E alone (P < 0.05). Infusion of PAF followed by or coincident with oxytocin (OT) acted in a synergistic manner to increase plasma PGFM levels. Repeated infusion of PAF into the uterus at 1-h intervals induced tachyphylaxis of the PGFM response to PAF; however, sensitivity of the uterus to PAF returned spontaneously by the 6th h. Interferon-tau (IFN-tau) inhibits pulsatile release of PGF2alpha during pregnancy to prevent luteolysis. Exogenous recombinant ovine IFN-tau (50 microgram) inhibited the uterine response to PAF alone or the combined effects of PAF and OT. These results indicate that uterine PAF fulfills many of the criteria for an endogenous PGF2alpha pulse-generator: steroid induction of PAF production and uterine responsiveness to PAF-induced release of PGF; synergistic stimulation of PAF-induced PGF release by OT; inhibition of PAF effects by IFN-tau; and PAF's ability to induce pulses of PGF with a periodicity during a period of chronic exposure of the uterus to PAF. (+info)Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma. (7/562)
A region of 150 kb has been analysed around a previously isolated, lymphoma associated, translocation breakpoint located at chromosome band 11q23. This balanced and reciprocal translocation, t(11;14)(q32;q23), has been shown to result in the fusion between chromosome 11 specific sequence and the switch gamma4 region of the IGH locus. The LPC gene, encoding a novel proprotein convertase belonging to the furin family, has been identified in this region. In order to characterize further the region surrounding the translocation, we have determined the detailed structure of LPC. Here we show that LPC consists of at least 16 exons covering 25 kb, and that there is a partial duplication, involving mobile genetic elements and containing LPC exons 13-17 in a tail-tail configuration at 65 kb downstream. Since the chromosomal breakpoint lay between these two structures, the intervening region was further analysed and shown to contain at least two unrelated genes. The previously known SM22 gene was localized close to the 3' tail of LPC. Furthermore, we identified the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) at the chromosomal breakpoint. The position of another previously identified breakpoint was also located to within the first intron of this gene. Altogether, our results give evidence of a genomic instability of this area of 11q23 and show that Pafah1a2 and not LPC is the gene disrupted by the translocation, suggesting that deregulated Pafah1a2 may have a role in lymphomagenesis. (+info)All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. (8/562)
Mildly oxidized LDL has many proinflammatory properties, including the stimulation of monocyte chemotaxis and adhesion, that are important in the development of atherosclerosis. Although ApoB-containing lipoproteins other than LDL may enter the artery wall and undergo oxidation, very little is known regarding their proinflammatory potential. LDL, IDL, VLDL, postprandial remnant particles, and chylomicrons were mildly oxidized by fibroblasts overexpressing 15-lipoxygenase (15-LO) and tested for their ability to stimulate monocyte chemotaxis and adhesion to endothelial cells. When conditioned on 15-LO cells, LDL, IDL, but not VLDL increased monocyte chemotaxis and adhesion approximately 4-fold. Chylomicrons and postprandial remnant particles were also bioactive. Although chylomicrons had a high 18:1/18:2 ratio, similar to that of VLDL, and should presumably be less susceptible to oxidation, they contained (in contrast to VLDL) essentially no platelet-activating factor acetylhydrolase (PAF-AH) activity. Because PAF-AH activity of lipoproteins may be reduced in vivo by oxidation or glycation, LDL, IDL, and VLDL were treated in vitro to reduce PAF-AH activity and then conditioned on 15-lipoxygenase cells. All 3 PAF-AH-depleted lipoproteins, including VLDL, exhibited increased stimulation of monocyte chemotaxis and adhesion. In a similar manner, lipoproteins from Japanese subjects with a deficiency of plasma PAF-AH activity were also markedly more bioactive, and stimulated monocyte adhesion nearly 2-fold compared with lipoproteins from Japanese control subjects with normal plasma PAF-AH. For each lipoprotein, bioactivity resided in the lipid fraction and monocyte adhesion could be blocked by PAF-receptor antagonists. These data suggest that the susceptibility of plasma lipoproteins to develop proinflammatory activity is in part related to their 18:1/18:2 ratio and PAF-AH activity, and that bioactive phospholipids similar to PAF are generated during oxidation of each lipoprotein. Moreover, LDL, IDL, postprandial remnant particles, and chylomicrons and PAF-AH-depleted VLDL all give rise to proinflammatory lipids when mildly oxidized. (+info)
Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein | Biochemical...
Lipoprotein-associated phospholipase A2 - Wikipedia
The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease | Bentham Science
PAFAH2 - Wikipedia
openarchives.gr | Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis...
Structure Cluster
- 1ES9: X-RAY CRYSTAL STRUCTURE OF R22K MUTANT OF THE MAMMALIAN BRAIN PLATELET-ACTIVATING FACTOR...
Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2...
Lipoprotein associated phospholipase A2 measurement
- Loyola University Health System
Lipoprotein-Associated Phospholipase A2 Activity Improves Risk Discrimination of Incident Coronary Heart Disease Among Women
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart...
Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation...
Is Lipoprotein-Associated Phospholipase A2a Link between Inflammation and Subclinical Atherosclerosis inRheumatoid Arthritis?
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non...
Lipoprotein-associated Phospholipase Inhibition Regulates Retinal Vasopermeability During Experimental Diabetes | IOVS | ARVO...
Lipoprotein-Associated Phospholipase A2 Test - Request A Test
Kidney Function Decline in the Elderly: Impact of Lipoprotein-Associated Phospholipase A2 - FullText - American Journal of...
Pafah1b3 - Platelet-activating factor acetylhydrolase IB subunit gamma - Mus musculus (Mouse) - Pafah1b3 gene & protein
Sequence Similarity
- 1FXW: CRYSTAL STRUCTURE OF THE RECOMBINANT ALPHA1/ALPHA2 CATALYTIC HETERODIMER OF BOVINE BRAIN...
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 | Arteriosclerosis, Thrombosis, and...
Xarelto | Evolution of NADPH Oxidase Inhibitors
Abstract 14551: LpPLA2 Activity and Mass Are Distributed Across Subfractions of Both LDL and HDL, and Relate Differently to CHD...
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary...
OriGene - PAFAH1B2 (NM 002572) Human ORF cDNA Clone
OriGene - Pafah1b2 (NM 008775) cDNA Clone
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans - Full Text View -...
High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and...
Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy...
Circulating Levels of Secretory- and Lipoprotein-Associated Phospholipase A2 Activities: Relation to Atherosclerotic Plaques...
Lipoprotein-Associated Phospholipase A2 - Gundersen Health System - La Crosse, Wisconsin
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2 - INTEGRIS OK
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2
Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus
Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community | Arteriosclerosis,...
Lipoprotein-associated phospholipase A2 (Lp‑PLA<sub>2</sub>) - DiaSys Diagnostic...
Human lipoprotein-associated phospholipase A2 , Lp-PLA2 ELISA Kit
Lipoprotein-Associated Phospholipase A2 Activity, Serum (PLACA) Test Sheet - Insights
ivd-test-reagent-kits-immunoassay-lipoprotein-associated-enzyme-phospholipase-a2
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The...
Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene
Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event | EurekAlert! Science News
can manifest efectos proscar alopecia Mosby- Year
Dental News Report: Gum disease = risk for cardiovascular disease
Corrigendum to Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported...
Lipoprotein-associated Phospholipase A2 and Serum Lipid Levels in Supjects with Chronic Periodontitis and Hyperlipidemia
Lipoprotein-Associated Phospholipase A2 - AHealthyMe - Blue Cross Blue Shield of Massachusetts
Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits. | Stroke
Lp-PLA2 and Coronary Atherosclerosis in Humans - Full Text View - ClinicalTrials.gov
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA) | Lipids in Health and Disease ...
PAFAH Ib phospholipase A2 subunits have distinct roles in maintaining Golgi structure and function.
platelet-activating factor
Plus it
State of the art paper Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated...
Miller-Dieker Syndrome | SpringerLink
Tissue expression of PAFAH1B1 - Staining in lung - The Human Protein Atlas
PAFAH1B1 (Human) Recombinant Protein (P01) - (H00005048-P01) - Products - Abnova
Tissue expression of PAFAH1B3 - Summary - The Human Protein Atlas
NKFI-EPR:Ischaemiás-reperfusiós károsodások funkcionális és strukturális változásainak kivédése különböző (máj, vékonybél,...
A becs lt n triumbevitel sszef gg se a sz v anat miai s funkcion lis k rosod s val. A HyperGEN tanulm ny eredm nyei
Az intracraniális hemodinamika és a Willis-kör morfológiai jelentősége a carotis rekonstrukciós műtéteinél
Lis (Lactulose) Lisapharma
Panasonic NV-GS500 tip. 3CCD-s digit lis DV kamera, doboz ban elad ! - Sz kesfeh rv r, Fej r
QUICK FIX BLISTER Univerzális pillanatragasztó - cianoakrilá
Вторая вакцина с проблемами, и прочее: chuka lis - LiveJournal
Topical - Page 5 of 5 - Mylab
Reflux-betegség | Blausen Medical
Avatar-kauppa
Pälkäne, Pirkanmaa
Inari, Lappi
List of MeSH codes (D08)
... naphthol as d esterase MeSH D08.811.277.352.100.680 - phospholipases MeSH D08.811.277.352.100.680.510 - lysophospholipase MeSH ... cholesterol esterase MeSH D08.811.277.352.100.170 - cholinesterases MeSH D08.811.277.352.100.170.176 - acetylcholinesterase ... endo-1,4-beta xylanases MeSH D08.811.277.450.950.500 - xylan endo-1,3-beta-xylosidase MeSH D08.811.277.656.149 - atp-dependent ... glucan 1,4-beta-glucosidase MeSH D08.811.277.450.420.200.600 - glucan endo-1,3-beta-d-glucosidase MeSH D08.811.277.450.420.375 ...
1-alkyl-2-acetylglycerophosphocholine esterase
256 (1): 175-8. PMID 7451433. PAF+acetylhydrolase at the US National Library of Medicine Medical Subject Headings (MeSH) EC 3.1 ... The enzyme 1-alkyl-2-acetylglycerophosphocholine esterase (EC 3.1.1.47) catalyzes the reaction 1-alkyl-2-acetyl-sn-glycero-3- ... The systematic name of this enzyme class is 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetohydrolase. Other names in common ... Blank ML, Lee T, Fitzgerald V, Snyder F (1981). "A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a ...
List of EC numbers (EC 3)
... apo-salmochelin esterase * EC 3.1.1.108: iron(III)-enterobactin esterase * EC 3.1.1.109: iron(III)-salmochelin esterase * EC ... acetylxylan esterase EC 3.1.1.73: feruloyl esterase EC 3.1.1.74: cutinase EC 3.1.1.75: poly(3-hydroxybutyrate) depolymerase EC ... polyneuridine-aldehyde esterase EC 3.1.1.79: hormone-sensitive lipase EC 3.1.1.80: acetylajmaline esterase EC 3.1.1.81: quorum- ... methyl ester esterase EC 3.1.1.86: rhamnogalacturonan acetylesterase EC 3.1.1.87: fumonisin B1 esterase EC 3.1.1.88: pyrethroid ...
Code System Concept
1-Alkyl-2-acetylglycerophosphocholine esterase Current Synonym true false 3040606019 Lipoprotein associated phospholipase A2 ... 1-alkyl-2-acetylglycerophosphocholine esterase (substance). Code System Preferred Concept Name. 1-alkyl-2- ... acetylglycerophosphocholine esterase (substance). Concept Status. Published. Concept Status Date. 09/01/2020. ...
Code System Concept
Chloracetate esterase (substance) {259725001 , SNOMED-CT } Cholesterol esterase (substance) {50622004 , SNOMED-CT } Dornase ... Alpha-amino-acid esterase (substance) {50854006 , SNOMED-CT } Alpha-naphthyl acetate esterase (substance) {115330006 , SNOMED- ... Esterase (substance) {130196001 , SNOMED-CT } Parent/Child (Relationship Type) 1-alkyl-2-acetylglycerophosphocholine esterase ( ... Retinyl-palmitate esterase (substance) {24307008 , SNOMED-CT } Streptodornase (substance) {123685004 , SNOMED-CT } Tannase ( ...
Bond University Nutrition and Dietetics Research Group - Research Outputs
- Bond University Research Portal
English, C. J., Mayr, H. L., Lohning, A. E. & Reidlinger, D. P., 1 Jun 2022, In: Nutrition Reviews. 80, 6, p. 1371-1391 21 p., ... Murray, E. M., Hickman, I. J., Isbel, N. M. & Campbell, K. L., Sep 2015, In: Nephrology. 20, S3, p. 58-58 1 p., 150.. Research ... Crichton, M., Marx, W., Lohning, A. E., Isenring, E. & Marshall, S., Aug 2020, In: Nutrition and Dietetics. 77, S1, p. 29-27 2 ... Desbrow, B., Irwin, C., Delang, N. & Cox, G. R., Jul 2020, In: Medicine and Science in Sports and Exercise. 52, 7S, p. 170 1 p. ...
ENZYME: 3.-.-.
... apo-salmochelin esterase 3.1.1.108 iron(III) enterobactin esterase 3.1.1.109 iron(III) salmochelin esterase 3.1.1.110 xylono-1, ... acetylxylan esterase 3.1.1.73 feruloyl esterase 3.1.1.74 cutinase 3.1.1.75 poly(3-hydroxybutyrate) depolymerase 3.1.1.76 poly(3 ... methyl ester esterase 3.1.1.86 rhamnogalacturonan acetylesterase 3.1.1.87 fumonisin B1 esterase 3.1.1.88 pyrethroid hydrolase ... alpha-amino-acid esterase 3.1.1.44 4-methyloxaloacetate esterase 3.1.1.45 carboxymethylenebutenolidase 3.1.1.46 deoxylimonate A ...
SMART: Pfam domain PAF-AH p II
Platelet-activating factor acetylhydrolase (PAF-AH) is a subfamily of phospholipase A2, and is involved in regulation of inflammation through the inactivation of platelet-activating factor and polar phospholipids [ (PUBMED:9645224) ]. ...
Human PLA2G7/PAF-AH/Lp-PLA2 Antibody MAB51061-100: R&D Systems
Secretory phopholipase A2 is an enzyme that hydrolyses the Sn-2 ester bond of phospholipids, generating free fatty acids and ... 1 month, 2 to 8 °C under sterile conditions after reconstitution.. *6 months, -20 to -70 °C under sterile conditions after ... Human PLA2G7/PAF‑AH/Lp‑PLA2 ELISA Standard Curve. Recombinant Human PLA2G7/PAF-AH/Lp-PLA2 protein was serially diluted 2-fold ... In contrast to other classical sPLA2s, PLA2G‑VII has poor specificity toward Sn-2 long chain fatty acids, unless heavily ...
LongText Report for: 5ye9-pdb
6 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE,2-ACETYL-1- COMPND 7 ALKYLGLYCEROPHOSPHOCHOLINE ESTERASE,GROUP-VIIA PHOSPHOLIPASE A2, ... 2 AA110 VAL A 65 PHE A 72 1 N VAL A 65 O ASN A 133 SHEET 3 AA110 THR A 79 PRO A 86 -1 O TYR A 85 N GLY A 66 SHEET 4 AA110 ILE A ... 2 AA410 VAL B 65 PHE B 72 1 N VAL B 65 O ASN B 133 SHEET 3 AA410 THR B 79 PRO B 86 -1 O TYR B 85 N GLY B 66 SHEET 4 AA410 ILE B ... 1 O ILE A 417 N THR A 345 SHEET 1 AA2 2 THR A 95 LEU A 96 0 SHEET 2 AA2 2 THR A 129 THR A 130 -1 O THR A 130 N THR A 95 SHEET 1 ...
Department of Medicine - Research output
- Creighton University
Gupta, P., Giehler, K., Walters, R. W., Meyerink, K. & Modrykamien, A. M., Feb 1 2014, In: Respiratory Care. 59, 2, p. 170-177 ... Gallagher, J. C., Jindal, P. S. & Smith, L. M., Jan 1 2014, In: Journal of Bone and Mineral Research. 29, 1, p. 173-181 9 p.. ... Tarasova, V. D., Trepp-Carrasco, A. G., Thompson, R., Recker, R. R., Chong, W. H., Collins, M. T. & Armas, L. A. G., Nov 1 2013 ... Heaney, R. P., Jan 2014, In: Nutrition Reviews. 72, 1, p. 48-54 7 p.. Research output: Contribution to journal › Article › peer ...
Bond University Nutrition and Dietetics Research Group - Research Outputs
- Bond University Research Portal
Law, L., Kelly, J. T., Savill, H., Wallen, M. P., Hickman, I. J., Erku, D. & Mayr, H., 2 Feb 2022, (E-pub ahead of print) In: ... English, C. J., Mayr, H. L., Lohning, A. E. & Reidlinger, D. P., 1 Jun 2022, In: Nutrition Reviews. 80, 6, p. 1371-1391 21 p., ... Bailey, N. W., Bridgman, T. K., Marx, W. & Fitzgerald, P. B., 1 Dec 2016, In: Mindfulness. 7, 6, p. 1249-1255 7 p.. Research ... Crichton, M., Davidson, A. R., Innerarity, C., Marx, W., Lohning, A., Isenring, E. & Marshall, S., 1 Jun 2022, In: American ...
i5k - EOG8ZSCHK
Site designed and maintained by Gregg Thomas, 2017 , Some of the CSS used to design this site is from the Pure CSS project. , Banner image ...
Geisha
platelet-activating factor acetylhydrolase,1-alkyl-2-acetylglycerophosphocholine esterase,2-acetyl-1-alkylglycerophosphocholine ... esterase,LDL-PLA(2),LDL-associated phospholipase A2,PAF 2-acylhydrolase,PAF acetylhydrolase,phospholipase A2, group VII ( ...
Gene locus Report for: mizye-a0a210q4j1
2 UniProt : A0A210Q4J1, B1A9T4. 2 Interpro : A0A210Q4J1, B1A9T4. 2 Prodom : A0A210Q4J1, B1A9T4. 2 Pfam : A0A210Q4J1, B1A9T4. 2 ... Ref: Nat Ecol Evol, 1:120, 2017 : PubMed. Abstract. ESTHER: Wang_2017_Nat.Ecol.Evol_1_120. PubMedSearch: Wang 2017 Nat.Ecol. ... Evol 1 120. PubMedID: 28812685. Gene_locus related to this paper: mizye-a0a210qls6, mizye-a0a210qis3, mizye-a0a210qg00, mizye- ... ACHE : mizye-a0a210qls6Mizuhopecten yessoensis (Japanese scallop) (Patinopecten yessoensis). Acetylcholinesterase PYE-5989.14.1 ...
3.1.1.47: 1-alkyl-2-acetylglycerophosphocholine esterase - BRENDA Enzyme Database
1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. + H2O. = 1-alkyl-sn-glycero-3-phosphocholine. + acetate. ... 3.1.1.47: 1-alkyl-2-acetylglycerophosphocholine esterase. This is an abbreviated version!. For detailed information about 1- ... More, 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine: acetylhydrolase, alkylacetyl-GPC:acetylhydrolase, deacetylase, 1-alkyl-2- ... 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetylhydrolase, type I platelet-activating factor acetylhydrolase, plasma PAF ...
A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3. | Profiles RNS
Chong SS, Pack SD, Roschke AV, Tanigami A, Carrozzo R, Smith AC, Dobyns WB, Ledbetter DH. A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3. Hum Mol Genet. 1997 Feb; 6(2):147-55 ...
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32...
FINDINGS: Lp-PLA(2) activity and mass were associated with each other (r=0.51, 95% CI 0.47-0.56) and proatherogenic lipids. We ... INTERPRETATION: Lp-PLA(2) activity and mass each show continuous associations with risk of coronary heart disease, similar in ... RRs, adjusted for conventional risk factors, were: 1.10 (95% CI 1.05-1.16) with Lp-PLA(2) activity and 1.11 (1.07-1.16) with Lp ... RRs with Lp-PLA(2) did not differ significantly in people with and without initial stable vascular disease, apart from for ...
MMTB
3.1.1.59 juvenile-hormone esterase 3.1.1.72 acetylxylan esterase 3.1.1.73 feruloyl esterase - - - - - ... phthalate esterase 3.1.1.72 acetylxylan esterase 3.1.1.73 feruloyl esterase 3.1.1.74 cutinase 3.1.1.75 poly(3-hydroxybutyrate) ... 3.1.1.108 iron(III)-enterobactin esterase 3.1.1.13 sterol esterase 3.1.1.2 arylesterase 3.1.1.23 acylglycerol lipase 3.1.1.3 ... 2 1-octyne + 2 NADH + 2 H+ + 2 O2 <=> Octanoate + 7-octynoic_acid + 2 NAD+ + 2 H2O 1.14.15.3 alkane 1-monooxygenase - ...
Aileen P. McGinn - Publications
- Albert Einstein College of Medicine
Tanenbaum, E. J., Johnson, J. H., Jordan, E., Cottral, J., Tenore, C., Burton, W. B., McGinn, A. P. & Raff, A. C., Dec 1 2016, ... Hochfelder, C. G., McGinn, A. P., Mehta, V., Castellucci, E., Kabarriti, R. & Ow, T. J., Nov 1 2020, In: Laryngoscope. 130, 11 ... Hawks, R. M., McGinn, A. P., Bernstein, P. S. & Tobin, J. N., Aug 1 2018, In: Maternal and child health journal. 22, 8, p. 1103 ... Khan, U. I., McGinn, A. P., Isasi, C. R., Groisman-Perelstein, A., Diamantis, P. M., Ginsberg, M. & Wylie-Rosett, J., Jun 1 ...
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) as a Marker of Coronary Heart Disease - Fingerprint
- Universitas...
Dive into the research topics of 'Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) as a Marker of Coronary Heart Disease'. Together they form a unique fingerprint. ...
US8454994B2 - Stable pharmaceutical composition and methods of using same
- Google Patents
125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1 * ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-ethylpyrrolidin-2-one ... 229940068917 Polyethylene Glycols Drugs 0.000 description 2 * 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description ... 206010030113 Oedema Diseases 0.000 description 2 * 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description ... 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2 * 229920003171 Poly (ethylene oxide) Polymers 0.000 ...
A pleiotropic QTL on 2p influences serum Lp-PLA<sub>2</sub> activity and LDL cholesterol concentration in a baboon model for...
Y1 - 2008/2. N2 - Lipoprotein-associated phospholipase A2 (Lp-PLA2), the major portion of which is bound to low-density ... 2, 02.2008, p. 667-673.. Research output: Contribution to journal › Article › peer-review ... The QTL-specific correlation between the traits (ρQ = 0.62) was significantly different from both zero and 1 (P[ρQ = 0] = 0.047 ... A pleiotropic QTL on 2p influences serum Lp-PLA2 activity and LDL cholesterol concentration in a baboon model for the genetics ...
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary...
Y1 - 2005/1. N2 - Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary ... 2, 01.2005, p. 137-144.. Research output: Contribution to journal › Article › peer-review ... European heart journal, 26(2), 137-144. https://doi.org/10.1093/eurheartj/ehi010 ...
Clinical and molecular basis of classical lissencephaly: Mutations in the LIS1 gene (PAFAH1B1). | Profiles RNS
Cardoso C, Leventer RJ, Dowling JJ, Ward HL, Chung J, Petras KS, Roseberry JA, Weiss AM, Das S, Martin CL, Pilz DT, Dobyns WB, Ledbetter DH. Clinical and molecular basis of classical lissencephaly: Mutations in the LIS1 gene (PAFAH1B1). Hum Mutat. 2002 Jan; 19(1):4-15 ...
1-alkyl-2-acetylglycerophosphocholine esterase - Wikipedia
256 (1): 175-8. PMID 7451433. PAF+acetylhydrolase at the US National Library of Medicine Medical Subject Headings (MeSH) EC 3.1 ... The enzyme 1-alkyl-2-acetylglycerophosphocholine esterase (EC 3.1.1.47) catalyzes the reaction 1-alkyl-2-acetyl-sn-glycero-3- ... The systematic name of this enzyme class is 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetohydrolase. Other names in common ... Blank ML, Lee T, Fitzgerald V, Snyder F (1981). "A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a ...
3.1.1.47: 1-alkyl-2-acetylglycerophosphocholine esterase - BRENDA Enzyme Database
1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. + H2O. = 1-alkyl-sn-glycero-3-phosphocholine. + acetate. ... 3.1.1.47: 1-alkyl-2-acetylglycerophosphocholine esterase. This is an abbreviated version!. For detailed information about 1- ... More, 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine: acetylhydrolase, alkylacetyl-GPC:acetylhydrolase, deacetylase, 1-alkyl-2- ... 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetylhydrolase, type I platelet-activating factor acetylhydrolase, plasma PAF ...
US8454994B2 - Stable pharmaceutical composition and methods of using same - Google Patents
125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1 * ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-ethylpyrrolidin-2-one ... 229940068917 Polyethylene Glycols Drugs 0.000 description 2 * 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description ... 206010030113 Oedema Diseases 0.000 description 2 * 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description ... 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2 * 229920003171 Poly (ethylene oxide) Polymers 0.000 ...
SMART: Pfam domain PAF-AH p II
Code System Concept
1-Alkyl-2-acetylglycerophosphocholine esterase Current Synonym true false 3040606019 Lipoprotein associated phospholipase A2 ... 1-alkyl-2-acetylglycerophosphocholine esterase (substance). Code System Preferred Concept Name. 1-alkyl-2- ... acetylglycerophosphocholine esterase (substance). Concept Status. Published. Concept Status Date. 09/01/2020. ...
Geisha
A pleiotropic QTL on 2p influences serum Lp-PLA<sub>2</sub> activity and LDL cholesterol concentration in a baboon model for...
Y1 - 2008/2. N2 - Lipoprotein-associated phospholipase A2 (Lp-PLA2), the major portion of which is bound to low-density ... 2, 02.2008, p. 667-673.. Research output: Contribution to journal › Article › peer-review ... The QTL-specific correlation between the traits (ρQ = 0.62) was significantly different from both zero and 1 (P[ρQ = 0] = 0.047 ... A pleiotropic QTL on 2p influences serum Lp-PLA2 activity and LDL cholesterol concentration in a baboon model for the genetics ...
Gene locus Report for: mizye-a0a210q4j1
2 UniProt : A0A210Q4J1, B1A9T4. 2 Interpro : A0A210Q4J1, B1A9T4. 2 Prodom : A0A210Q4J1, B1A9T4. 2 Pfam : A0A210Q4J1, B1A9T4. 2 ... Ref: Nat Ecol Evol, 1:120, 2017 : PubMed. Abstract. ESTHER: Wang_2017_Nat.Ecol.Evol_1_120. PubMedSearch: Wang 2017 Nat.Ecol. ... Evol 1 120. PubMedID: 28812685. Gene_locus related to this paper: mizye-a0a210qls6, mizye-a0a210qis3, mizye-a0a210qg00, mizye- ... ACHE : mizye-a0a210qls6Mizuhopecten yessoensis (Japanese scallop) (Patinopecten yessoensis). Acetylcholinesterase PYE-5989.14.1 ...
Department of Medicine - Research output - Creighton University
Gupta, P., Giehler, K., Walters, R. W., Meyerink, K. & Modrykamien, A. M., Feb 1 2014, In: Respiratory Care. 59, 2, p. 170-177 ... Gallagher, J. C., Jindal, P. S. & Smith, L. M., Jan 1 2014, In: Journal of Bone and Mineral Research. 29, 1, p. 173-181 9 p.. ... Tarasova, V. D., Trepp-Carrasco, A. G., Thompson, R., Recker, R. R., Chong, W. H., Collins, M. T. & Armas, L. A. G., Nov 1 2013 ... Heaney, R. P., Jan 2014, In: Nutrition Reviews. 72, 1, p. 48-54 7 p.. Research output: Contribution to journal › Article › peer ...
Bond University Nutrition and Dietetics Research Group - Research Outputs - Bond University Research Portal
Law, L., Kelly, J. T., Savill, H., Wallen, M. P., Hickman, I. J., Erku, D. & Mayr, H., 2 Feb 2022, (E-pub ahead of print) In: ... English, C. J., Mayr, H. L., Lohning, A. E. & Reidlinger, D. P., 1 Jun 2022, In: Nutrition Reviews. 80, 6, p. 1371-1391 21 p., ... Bailey, N. W., Bridgman, T. K., Marx, W. & Fitzgerald, P. B., 1 Dec 2016, In: Mindfulness. 7, 6, p. 1249-1255 7 p.. Research ... Crichton, M., Davidson, A. R., Innerarity, C., Marx, W., Lohning, A., Isenring, E. & Marshall, S., 1 Jun 2022, In: American ...
Aileen P. McGinn - Publications
- Albert Einstein College of Medicine
Tanenbaum, E. J., Johnson, J. H., Jordan, E., Cottral, J., Tenore, C., Burton, W. B., McGinn, A. P. & Raff, A. C., Dec 1 2016, ... Hochfelder, C. G., McGinn, A. P., Mehta, V., Castellucci, E., Kabarriti, R. & Ow, T. J., Nov 1 2020, In: Laryngoscope. 130, 11 ... Hawks, R. M., McGinn, A. P., Bernstein, P. S. & Tobin, J. N., Aug 1 2018, In: Maternal and child health journal. 22, 8, p. 1103 ... Khan, U. I., McGinn, A. P., Isasi, C. R., Groisman-Perelstein, A., Diamantis, P. M., Ginsberg, M. & Wylie-Rosett, J., Jun 1 ...
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) as a Marker of Coronary Heart Disease - Fingerprint - Universitas...
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary...
Y1 - 2005/1. N2 - Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary ... 2, 01.2005, p. 137-144.. Research output: Contribution to journal › Article › peer-review ... European heart journal, 26(2), 137-144. https://doi.org/10.1093/eurheartj/ehi010 ...
Bond University Nutrition and Dietetics Research Group - Research Outputs - Bond University Research Portal
English, C. J., Mayr, H. L., Lohning, A. E. & Reidlinger, D. P., 1 Jun 2022, In: Nutrition Reviews. 80, 6, p. 1371-1391 21 p., ... Murray, E. M., Hickman, I. J., Isbel, N. M. & Campbell, K. L., Sep 2015, In: Nephrology. 20, S3, p. 58-58 1 p., 150.. Research ... Crichton, M., Marx, W., Lohning, A. E., Isenring, E. & Marshall, S., Aug 2020, In: Nutrition and Dietetics. 77, S1, p. 29-27 2 ... Desbrow, B., Irwin, C., Delang, N. & Cox, G. R., Jul 2020, In: Medicine and Science in Sports and Exercise. 52, 7S, p. 170 1 p. ...
Human PLA2G7/PAF-AH/Lp-PLA2 Antibody MAB51061-100: R&D Systems
Secretory phopholipase A2 is an enzyme that hydrolyses the Sn-2 ester bond of phospholipids, generating free fatty acids and ... 1 month, 2 to 8 °C under sterile conditions after reconstitution.. *6 months, -20 to -70 °C under sterile conditions after ... Human PLA2G7/PAF‑AH/Lp‑PLA2 ELISA Standard Curve. Recombinant Human PLA2G7/PAF-AH/Lp-PLA2 protein was serially diluted 2-fold ... In contrast to other classical sPLA2s, PLA2G‑VII has poor specificity toward Sn-2 long chain fatty acids, unless heavily ...
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32...
FINDINGS: Lp-PLA(2) activity and mass were associated with each other (r=0.51, 95% CI 0.47-0.56) and proatherogenic lipids. We ... INTERPRETATION: Lp-PLA(2) activity and mass each show continuous associations with risk of coronary heart disease, similar in ... RRs, adjusted for conventional risk factors, were: 1.10 (95% CI 1.05-1.16) with Lp-PLA(2) activity and 1.11 (1.07-1.16) with Lp ... RRs with Lp-PLA(2) did not differ significantly in people with and without initial stable vascular disease, apart from for ...
ENZYME: 3.-.-.
... apo-salmochelin esterase 3.1.1.108 iron(III) enterobactin esterase 3.1.1.109 iron(III) salmochelin esterase 3.1.1.110 xylono-1, ... acetylxylan esterase 3.1.1.73 feruloyl esterase 3.1.1.74 cutinase 3.1.1.75 poly(3-hydroxybutyrate) depolymerase 3.1.1.76 poly(3 ... methyl ester esterase 3.1.1.86 rhamnogalacturonan acetylesterase 3.1.1.87 fumonisin B1 esterase 3.1.1.88 pyrethroid hydrolase ... alpha-amino-acid esterase 3.1.1.44 4-methyloxaloacetate esterase 3.1.1.45 carboxymethylenebutenolidase 3.1.1.46 deoxylimonate A ...
LongText Report for: 5ye9-pdb
6 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE,2-ACETYL-1- COMPND 7 ALKYLGLYCEROPHOSPHOCHOLINE ESTERASE,GROUP-VIIA PHOSPHOLIPASE A2, ... 2 AA110 VAL A 65 PHE A 72 1 N VAL A 65 O ASN A 133 SHEET 3 AA110 THR A 79 PRO A 86 -1 O TYR A 85 N GLY A 66 SHEET 4 AA110 ILE A ... 2 AA410 VAL B 65 PHE B 72 1 N VAL B 65 O ASN B 133 SHEET 3 AA410 THR B 79 PRO B 86 -1 O TYR B 85 N GLY B 66 SHEET 4 AA410 ILE B ... 1 O ILE A 417 N THR A 345 SHEET 1 AA2 2 THR A 95 LEU A 96 0 SHEET 2 AA2 2 THR A 129 THR A 130 -1 O THR A 130 N THR A 95 SHEET 1 ...
A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3. | Profiles RNS
MMTB
3.1.1.59 juvenile-hormone esterase 3.1.1.72 acetylxylan esterase 3.1.1.73 feruloyl esterase - - - - - ... phthalate esterase 3.1.1.72 acetylxylan esterase 3.1.1.73 feruloyl esterase 3.1.1.74 cutinase 3.1.1.75 poly(3-hydroxybutyrate) ... 3.1.1.108 iron(III)-enterobactin esterase 3.1.1.13 sterol esterase 3.1.1.2 arylesterase 3.1.1.23 acylglycerol lipase 3.1.1.3 ... 2 1-octyne + 2 NADH + 2 H+ + 2 O2 <=> Octanoate + 7-octynoic_acid + 2 NAD+ + 2 H2O 1.14.15.3 alkane 1-monooxygenase - ...
i5k - EOG8ZSCHK
White Blood Cell Count Predicts All-Cause Mortality in Patients with Suspected Peripheral Arterial Disease<...
TY - JOUR. T1 - White Blood Cell Count Predicts All-Cause Mortality in Patients with Suspected Peripheral Arterial Disease. AU - Arain, Faisal A.. AU - Khaleghi, Mahyar. AU - Bailey, Kent R.. AU - Lahr, Brian D.. AU - Rooke, Thom W.. AU - Kullo, Iftikhar J.. N1 - Funding Information: Funding: Supported by National Institutes of Health grants HL75794 and HL81331. Dr Arain is supported by the National Institutes of Health Vascular Medicine Training Program K12 grant (HL 083797). PY - 2009/9. Y1 - 2009/9. N2 - Objective: We investigated whether markers of inflammation-white blood cell (WBC) count, C-reactive protein (CRP), and lipoprotein-associated phospholipase A2-are associated with mortality in patients referred for noninvasive lower-extremity arterial evaluation. Methods: Participants (n = 242, mean age 68 years, 54% men) were followed for a median of 71 months. Ankle-brachial index (ABI), WBC count, plasma CRP, and lipoprotein-associated phospholipase A2 were measured at the start of the ...
Novel enzymatic method for assaying Lp-PLA|sub|2|/sub| in serum - Fingerprint - Kyushu University
Institute for Translational Research - Publications - HSC
Johnson, L. A., Mauer, C., Jahn, D., Song, M., Wyshywaniuk, L., Hall, J. R., Balldin, V. H. & OBryant, S. E., 1 Apr 2013, In: ... Chaudhari, K., Sumien, N., Johnson, L., DAgostino, D., Edwards, M., Paxton, R. J., Hall, J. R. & OBryant, S. E., 1 Oct 2016, ... Johnson, L. A., Sohrabi, H. R., Hall, J. R., Kevin, T., Edwards, M., OBryant, S. E. & Martins, R. N., 1 Aug 2015, In: ... Edwards, M., Hall, J., Williams, B., Johnson, L. & OBryant, S., 2015, In: Journal of Alzheimers Disease. 49, 1, p. 221-228 8 ...
Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial -...
Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells<...
TY - JOUR. T1 - Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells. AU - Biancone, Luigi. AU - Cantaluppi, Vincenzo. AU - Segoloni, Giuseppe. AU - Boccellino, Mariarosaria. AU - Del Sorbo, Lorenzo. AU - Conaldi, Pier Giulio. AU - Tjoelker, Larry W.. AU - Maruyama, Shoici. AU - Cantu, Edward. AU - Stern, David. AU - Andres, Giuseppe. AU - Camussi, Giovanni. PY - 2000/10/27. Y1 - 2000/10/27. N2 - Background. Platelet-activating factor (PAF) is a phospholipid mediator of inflammation which has been implicated in rejection. The interaction of anti-α-galactosyl natural antibodies (anti-α gal Abs) with endothelial cells is the initial step for the development of xenograft rejection. In our study, we stimulated porcine aorthic endothelial cells (PAEC) with anti-α gal IgG to investigate the synthesis of PAF from PAEC and its biological consequences. Methods and Results. PAF was extracted and chromatografically purified from ...
ENZYME: 3.1.1.
... apo-salmochelin esterase 3.1.1.108 iron(III) enterobactin esterase 3.1.1.109 iron(III) salmochelin esterase 3.1.1.110 xylono-1, ... acetylxylan esterase 3.1.1.73 feruloyl esterase 3.1.1.74 cutinase 3.1.1.75 poly(3-hydroxybutyrate) depolymerase 3.1.1.76 poly(3 ... methyl ester esterase 3.1.1.86 rhamnogalacturonan acetylesterase 3.1.1.87 fumonisin B1 esterase 3.1.1.88 pyrethroid hydrolase ... alpha-amino-acid esterase 3.1.1.44 4-methyloxaloacetate esterase 3.1.1.45 carboxymethylenebutenolidase 3.1.1.46 deoxylimonate A ...
LongText Report for: 5jan-pdb
5 ESTERASE,2-ACETYL-1-ALKYLGLYCEROPHOSPHOCHOLINE ESTERASE,GROUP-VIIA COMPND 6 PHOSPHOLIPASE A2,GVIIA-PLA2,LDL-ASSOCIATED ... 1 O THR A 130 N THR A 95 SHEET 3 AA111 SER A 64 PHE A 72 1 N VAL A 65 O ASN A 133 SHEET 4 AA111 THR A 79 SER A 87 -1 O LEU A 83 ... 1 AC2 4 ARG A 92 LEU A 93 PRO A 325 ALA A 326 SITE 1 AC3 3 GLU A 285 HOH A 678 HOH A 719 SITE 1 AC4 7 ASP A 89 LEU A 153 GLU A ... 1 O ILE A 417 N THR A 345 SHEET 1 AA2 2 ALA A 186 TYR A 189 0 SHEET 2 AA2 2 SER A 202 TYR A 205 -1 O LEU A 204 N THR A 187 LINK ...
PINX1 and PAFAH1B2 - Wiki-MPM
MeSH Browser
Esterases [D08.811.277.352] * Carboxylic Ester Hydrolases [D08.811.277.352.100] * Phospholipases [D08.811.277.352.100.680] * ... sPLA(2) Term UI T316230. LexicalTag ABB. ThesaurusID NLM (2008). SPLA2 Phospholipases Term UI T689426. Date01/17/2007. ... sPLA(2) sPLA2 sPLA2s Registry Number. EC 3.1.1.4. Previous Indexing. Phospholipases A (1980-2007). Public MeSH Note. 2008; ... 1-Alkyl-2-acetylglycerophosphocholine Esterase [D08.811.277.352.100.680.750.937.249] * Phospholipases A2, Calcium-Independent [ ...
1.471
- The enzyme 1-alkyl-2-acetylglycerophosphocholine esterase (EC 3.1.1.47) catalyzes the reaction 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O ⇌ {\displaystyle \rightleftharpoons } 1-alkyl-sn-glycero-3-phosphocholine + acetate The former is also known as platelet-activating factor. (wikipedia.org)
Coronary Disease1
- Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. (ox.ac.uk)
Acetylhydrolase2
- There are multiple enzymes with this function: Lipoprotein-associated phospholipase A2 Platelet-activating factor acetylhydrolase 2, cytoplasmic Platelet-activating factor acetylhydrolase 1b: regulatory subunit 1, catalytic subunit 2, catalytic subunit 3 This enzyme belongs to the family of hydrolases, specifically those acting on carboxylic ester bonds. (wikipedia.org)
- Other names in common use include 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetylhydrolase, and alkylacetyl-GPC:acetylhydrolase. (wikipedia.org)
Phospholipase2
- Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), the major portion of which is bound to low-density lipoprotein, is an independent biomarker of cardiovascular disease risk. (elsevier.com)
- BACKGROUND: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. (ox.ac.uk)
Activity9
- To search for common genetic determinants of variation in both Lp-PLA 2 activity and LDL cholesterol (LDL-C) concentration, we assayed these substances in serum from 679 pedigreed baboons. (elsevier.com)
- Using a maximum likelihood-based variance components approach, we detected significant evidence for a QTL affecting Lp-PLA 2 activity (LOD = 2.79, genome-wide P = 0.039) and suggestive evidence for a QTL affecting LDL-C levels (LOD = 2.16) at the same location on the baboon ortholog of human chromosome 2p. (elsevier.com)
- 0.00001), we conducted bivariate linkage analyses of Lp-PLA 2 activity and LDL-C concentration. (elsevier.com)
- We conclude that polymorphisms at the QTL described in this study exert some genetic effects that are shared between Lp-PLA 2 activity and LDL-C concentration. (elsevier.com)
- We investigated associations of circulating Lp-PLA(2) mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances. (ox.ac.uk)
- FINDINGS: Lp-PLA(2) activity and mass were associated with each other (r=0.51, 95% CI 0.47-0.56) and proatherogenic lipids. (ox.ac.uk)
- We noted roughly log-linear associations of Lp-PLA(2) activity and mass with risk of coronary heart disease and vascular death. (ox.ac.uk)
- INTERPRETATION: Lp-PLA(2) activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. (ox.ac.uk)
- Associations of Lp-PLA(2) mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids. (ox.ac.uk)
Cytoplasmic1
- Most secretory PLA 2 s are stored in cytoplasmic granules and are released in the extracellular environment on appropriate cell activation. (rndsystems.com)
Enzyme2
- The systematic name of this enzyme class is 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetohydrolase. (wikipedia.org)
- Secretory phopholipase A 2 is an enzyme that hydrolyses the Sn -2 ester bond of phospholipids, generating free fatty acids and lysophospholipids (1‑3). (rndsystems.com)
Genes2
Protein1
- Recombinant Human PLA2G7/PAF-AH/Lp-PLA2 protein was serially diluted 2-fold and captured by Mouse Anti-Human PLA2G7/PAF-AH/Lp-PLA2 Monoclonal Antibody (Catalog # MAB51061) coated on a Clear Polystyrene Microplate (Catalog # DY990 ). (rndsystems.com)
Significantly1
- RRs with Lp-PLA(2) did not differ significantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA(2) mass. (ox.ac.uk)
Journal1
- European heart journal , 26 (2), 137-144. (elsevier.com)
Month1
- 1 month, 2 to 8 °C under sterile conditions after reconstitution. (rndsystems.com)
Phase1
- In contrast to other classical sPLA 2 s, PLA2G‑VII has poor specificity toward Sn -2 long chain fatty acids, unless heavily oxidized, and undergoes the catalysis of its substrates in the aqueous phase rather than at the interfacial surface of lipids. (rndsystems.com)
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A22
- A lipoprotein-associated PHOSPHOLIPASE A2 which modulates the action of PLATELET ACTIVATING FACTOR by hydrolyzing the SN-2 ester bond to yield the biologically inactive lyso-platelet-activating factor. (nih.gov)
- The early inflammatory biomarkers related to atherosclerosis, namely soluble vascular adhesion molecule-1 (sVCAM-1), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and lipoprotein-associated phospholipase A2 (Lp-PLA2), were compared with analyzed CFR, using TTE and adenosine or dipyridamole, measured within 2 weeks after coronary angiography. (springernature.com)
Platelet-activa1
- This gene encodes the non-catalytic alpha subunit of the intracellular Ib isoform of platelet-activating factor acteylhydrolase, a heterotrimeric enzyme that specifically catalyzes the removal of the acetyl group at the SN-2 position of platelet-activating factor (identified as 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine). (nih.gov)
Atherosclerosis1
- Methods-In a prospective case-cohort (n = 949) study in 12 762 apparently healthy, middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, we first examined whether Lp-PLA 2 and hs-CRP levels improved the area under the receiver operator characteristic curve (AUC) for 5-year ischemic stroke risk. (elsevier.com)
Stroke3
- Conclusion-Lp-PLA 2 and hs-CRP may be useful in individuals classified as intermediate risk for ischemic stroke by traditional risk factors. (elsevier.com)
- Stroke , 40 (2), 376-381. (elsevier.com)
- We investigated associations of circulating Lp-PLA(2) mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances. (nih.gov)
Coronary2
- We noted roughly log-linear associations of Lp-PLA(2) activity and mass with risk of coronary heart disease and vascular death. (nih.gov)
- INTERPRETATION: Lp-PLA(2) activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. (nih.gov)
Phospholipid1
- It has specificity for phospholipid substrates with short-chain residues at the SN-2 position, but inactive against long-chain phospholipids. (nih.gov)
Vascular3
- however, recent randomized trials of Lp-PLA 2 inhibition reported no beneficial effects on vascular diseases. (nih.gov)
- RRs with Lp-PLA(2) did not differ significantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA(2) mass. (nih.gov)
- Associations of Lp-PLA(2) mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids. (nih.gov)
Biological1
- However, the biological variation of Lp-PLA 2 activity and corresponding reference change value (RCV) is unknown which limits interpretation of results. (umn.edu)
Human1
- 1 Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States. (nih.gov)
Individuals2
- In East Asians, a loss-of-function variant in the PLA2G7 gene can be used to assess the effects of genetically determined lower Lp-PLA 2 METHODS: PLA2G7 V279F (rs76863441) was genotyped in 91 428 individuals randomly selected from the China Kadoorie Biobank of 0.5 M participants recruited in 2004-08 from 10 regions of China, with 7 years' follow-up. (nih.gov)
- We then examined how Lp-PLA 2 and hs-CRP levels altered classification of individuals into low-, intermediate-, or high-risk categories compared with traditional risk factors. (elsevier.com)
Risk1
- METHODS: With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA(2) or other risk factor. (nih.gov)
Population1
- 1 Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, UK. (nih.gov)